397 related articles for article (PubMed ID: 12884349)
1. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines.
Bradford CR; Zhu S; Ogawa H; Ogawa T; Ubell M; Narayan A; Johnson G; Wolf GT; Fisher SG; Carey TE
Head Neck; 2003 Aug; 25(8):654-61. PubMed ID: 12884349
[TBL] [Abstract][Full Text] [Related]
2. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.
Andrews GA; Xi S; Pomerantz RG; Lin CJ; Gooding WE; Wentzel AL; Wu L; Sidransky D; Grandis JR
Head Neck; 2004 Oct; 26(10):870-7. PubMed ID: 15390206
[TBL] [Abstract][Full Text] [Related]
3. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.
Cullen KJ; Newkirk KA; Schumaker LM; Aldosari N; Rone JD; Haddad BR
Cancer Res; 2003 Dec; 63(23):8097-102. PubMed ID: 14678959
[TBL] [Abstract][Full Text] [Related]
4. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.
Akervall J; Guo X; Qian CN; Schoumans J; Leeser B; Kort E; Cole A; Resau J; Bradford C; Carey T; Wennerberg J; Anderson H; Tennvall J; Teh BT
Clin Cancer Res; 2004 Dec; 10(24):8204-13. PubMed ID: 15623595
[TBL] [Abstract][Full Text] [Related]
5. p53 apoptotic response to DNA damage dependent on bcl2 but not bax in head and neck squamous cell carcinoma lines.
Crowe DL; Sinha UK
Head Neck; 2006 Jan; 28(1):15-23. PubMed ID: 16302195
[TBL] [Abstract][Full Text] [Related]
6. Mutant Nbs1 enhances cisplatin-induced DNA damage and cytotoxicity in head and neck cancer.
Tran HM; Shi G; Li G; Carney JP; O'Malley B; Li D
Otolaryngol Head Neck Surg; 2004 Oct; 131(4):477-84. PubMed ID: 15467621
[TBL] [Abstract][Full Text] [Related]
7. Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene.
Sánchez-Prieto R; Quintanilla M; Cano A; Leonart ML; Martin P; Anaya A; Ramón y Cajal S
Oncogene; 1996 Sep; 13(5):1083-92. PubMed ID: 8806698
[TBL] [Abstract][Full Text] [Related]
8. Association of caspase-8 mutation with chemoresistance to cisplatin in HOC313 head and neck squamous cell carcinoma cells.
Liu J; Uematsu H; Tsuchida N; Ikeda MA
Biochem Biophys Res Commun; 2009 Dec; 390(3):989-94. PubMed ID: 19852930
[TBL] [Abstract][Full Text] [Related]
9. The ARF-p16 gene locus in carcinogenesis and therapy of head and neck squamous cell carcinoma.
Yarbrough WG
Laryngoscope; 2002 Dec; 112(12):2114-28. PubMed ID: 12461329
[TBL] [Abstract][Full Text] [Related]
10. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells.
Chang FL; Ling YF; Lai MD
Anticancer Res; 2000; 20(1A):329-36. PubMed ID: 10769676
[TBL] [Abstract][Full Text] [Related]
11. Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck.
Fouret P; Temam S; Charlotte F; Lacau-St-Guily J
Br J Cancer; 2002 Dec; 87(12):1390-5. PubMed ID: 12454767
[TBL] [Abstract][Full Text] [Related]
12. Generation and molecular characterization of head and neck squamous cell lines of fanconi anemia patients.
van Zeeburg HJ; Snijders PJ; Pals G; Hermsen MA; Rooimans MA; Bagby G; Soulier J; Gluckman E; Wennerberg J; Leemans CR; Joenje H; Brakenhoff RH
Cancer Res; 2005 Feb; 65(4):1271-6. PubMed ID: 15735012
[TBL] [Abstract][Full Text] [Related]
13. p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck.
Henriksson E; Baldetorp B; Borg A; Kjellen E; Akervall J; Wennerberg J; Wahlberg P
Acta Oncol; 2006; 45(3):300-5. PubMed ID: 16644573
[TBL] [Abstract][Full Text] [Related]
14. Antisense cyclin D1 enhances sensitivity of head and neck cancer cells to cisplatin.
Wang MB; Yip HT; Srivatsan ES
Laryngoscope; 2001 Jun; 111(6):982-8. PubMed ID: 11404608
[TBL] [Abstract][Full Text] [Related]
15. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
16. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines.
Brachman DG; Beckett M; Graves D; Haraf D; Vokes E; Weichselbaum RR
Cancer Res; 1993 Aug; 53(16):3667-9. PubMed ID: 8339273
[TBL] [Abstract][Full Text] [Related]
17. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers.
Kropveld A; Rozemuller EH; Leppers FG; Scheidel KC; de Weger RA; Koole R; Hordijk GJ; Slootweg PJ; Tilanus MG
Lab Invest; 1999 Mar; 79(3):347-53. PubMed ID: 10092071
[TBL] [Abstract][Full Text] [Related]
18. All-trans-retinoic acid enhances the effect of adenovirus-mediated wild-type p53 gene transfer in head and neck squamous cell carcinoma.
Nakashima T; Sun SY; Lotan R; Fujiwara T; Yasumatsu R; Komiyama S; Clayman GL
Laryngoscope; 2001 Aug; 111(8):1459-64. PubMed ID: 11568584
[TBL] [Abstract][Full Text] [Related]
19. Effect of human papillomavirus-16 infection on CD8+ T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck.
Sirianni N; Ha PK; Oelke M; Califano J; Gooding W; Westra W; Whiteside TL; Koch WM; Schneck JP; DeLeo A; Ferris RL
Clin Cancer Res; 2004 Oct; 10(20):6929-37. PubMed ID: 15501971
[TBL] [Abstract][Full Text] [Related]
20. Effects of p53 or p27 overexpression on cyclooxygenase-2 gene expression in head and neck squamous cell carcinoma cell lines.
Lee DW; Park SW; Park SY; Heo DS; Kim KH; Sung MW
Head Neck; 2004 Aug; 26(8):706-15. PubMed ID: 15287038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]